Most Read Articles
Natalia Reoutova, 3 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).

Excessive fat intake bad for the prostate

09 Jun 2019

High intake levels of dietary fat contribute to an increased risk of developing prostate cancer (PCa), according to data from the San Antonio Biomarkers of Risk (SABOR) study.

The present analysis included 1,903 men participating in SABOR, among whom 229 developed PCa over a median follow-up of 8.9 years.

Compared with noncancer controls, PCa patients were older (mean age, 61.68 vs 58.68 years; p<0.001), had higher prostate-specific antigen (PSA; mean, 2.37 vs 1.29 ng/mL; p<0.001), lower body mass index (mean, 27.15 vs 28.26 kg/m2; p=0.002), and more likely to have a family history of PCa (39.7 percent vs 21.4 percent; p<0.001) and abnormal prostate exam (30.1 percent vs 16.3 percent; p<0.001) at baseline.

Analysis of food and nutrient intakes obtained using the Food Frequency Questionnaire revealed PCa risk to have positive associations with increased caloric intake of total saturated fatty acids (hazard ratio [HR], 1.19, 1.07–1.32; p=0.001) and total trans fatty acids (HR, 1.21, 1.08–1.35; p<0.001).

Meanwhile, there was a trend toward an elevated PCa risk with increasing intake of monounsaturated fatty acid (MUFA; HR per quintile, 1.14, 1.03–1.27) and cholesterol (HR per quintile, 1.13, 1.02–1.26).

These data provide further evidence that intake of dietary fat is an important predictor of PCa risk and that dietary modification of fatty acid intake may reduce this risk, according to researchers. In light of a renewed interest in PCa screening particularly for patients at high risk, dietary modification could be considered as a prevention strategy.

Potential mechanisms underlying the association between dietary fat intake and PCa risk involve the oxidative stress generated during fat metabolism and induction of prostatic inflammation. [Cancer Epidemiol 2011;35:353-361; Cancer Prev Res 2011;4:1590-1598; Prostate 2012;72:233-243]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 3 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).